NFJ Investment Group LLC Has $2.12 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

NFJ Investment Group LLC decreased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,131 shares of the biopharmaceutical company’s stock after selling 1,762 shares during the period. NFJ Investment Group LLC’s holdings in Ultragenyx Pharmaceutical were worth $2,118,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $33,000. UMB Bank n.a. increased its holdings in Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares in the last quarter. True Wealth Design LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth approximately $43,000. Values First Advisors Inc. bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $56,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $107,000. 97.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on RARE shares. HC Wainwright increased their target price on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Canaccord Genuity Group restated a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Finally, TD Cowen lifted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $87.46.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $46.67 on Wednesday. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The firm has a market capitalization of $4.31 billion, a P/E ratio of -7.21 and a beta of 0.56. The business has a fifty day moving average price of $51.63 and a 200-day moving average price of $48.79.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same period last year, the firm earned ($2.23) EPS. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.